Investigating how complement activation affects kidney injury in sepsis
Official title: Complement Activation in Sepsis
Funded at University of Colorado Denver · NIH-11142429 · Data updated 2026-11-12
This study is looking at how a certain protein in urine might help doctors predict kidney problems in people with sepsis, so they can find better ways to protect the kidneys in seriously ill patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | July 22, 2024 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $189,243 |
| NIH project number | 5K23DK140617-02 |
| Project ID | NIH-11142429 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include critically ill children and adults diagnosed with sepsis.
✕Less likely to help
Patients who do not have sepsis or those with chronic kidney disease may not benefit from this research.
What this research studies
This research focuses on understanding the role of complement activation in sepsis-associated acute kidney injury (SA-AKI), a serious condition affecting both children and adults. The study will enroll critically ill patients diagnosed with sepsis and measure levels of a specific protein, urine complement factor Ba, to see if it can predict the onset of kidney injury. By collecting and analyzing urine samples over time, researchers aim to establish a link between elevated urine Ba levels and severe kidney outcomes. The findings could pave the way for future therapeutic trials targeting complement activation to prevent kidney damage in sepsis patients.
Why it matters
Potential benefit: If successful, this research could lead to new methods for predicting and potentially preventing kidney injury in patients with sepsis.
How similar studies have gone: Previous research has shown promising results in understanding the role of complement activation in kidney injury, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Stenson, Erin K — University of Colorado Denver
- Study coordinator: Stenson, Erin K
Related research
Other NIH-funded projects on the same topics.
-
Role of blood flow mechanics and transfusion in sepsis-related tiny-cl vessel clots
A patient-focused look at how red blood cell flow and transfusions might influence tiny blood vessel clots and organ problems in sepsis.
-
STeroids and enhanced Antibiotics for sepsis in Africa with HIV/TB (STARS)
This grant tests whether adding steroids and stronger antibiotics helps adults with severe sepsis tied to HIV/TB in areas with high TB rates.
-
Steroids and better antibiotics for sepsis in people with AIDS in Africa
This study tests whether adding hydrocortisone and stronger antibiotics can improve survival for adults with sepsis who also have AIDS or advanced immune suppression in regions with high TB.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Role of MMP3 in heart dysfunction during sepsis
This research tests whether blocking MMP3 can protect the heart and improve survival during sepsis in adults.
-
Sepsis patient care guided by Ugandan-wide immune profiling
A large NIH-funded study will map how the immune system behaves during sepsis in people in Uganda to improve personalized care for sepsis patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.